MK-0616, an experimental oral medication aimed at reducing LDL cholesterol, is intended to be the first oral PCSK9 inhibitor.

Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other products. Read why MRK is a Buy.

Following a pre-Congress press briefing and data presented onsite at ASCO 2025 itself, pharmaphorum spoke with Dr Victoria ...

A new slate of vaccine advisers to the US Centers for Disease Control and Prevention voted Thursday to recommend that ...

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend use of ...

The votes in favor of Merck's shot are a sigh of relief after Kennedy gutted the panel and tapped replacements, some of whom ...

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

Robert F. Kennedy Jr.’s vaccine advisory committee recommended Merck & Co.’s shot to prevent newborns from getting RSV, ...

Iya Khalil, PhD, discusses Merck & Co.’s approach to artificial intelligence (AI), and success in applying the technology, ...